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autoSomal domInant PolycyStIc KIdney dISeaSe By end-Stage renal 
dISeaSe StatuS
Iyer NN1, Vendetti NJ2, Levy DI2, Mardekian J3, Mychaskiw MA2, Thomas III J1
1Purdue University, College of Pharmacy and Regenstrief Center for Healthcare Engineering, 
Center for Health Outcomes Research and Policy, West Lafayette, IN, USA, 2Pfizer Inc., Collegeville, 
PA, USA, 3Pfizer, Inc., New York, NY, USA
Objectives: Incremental health care resource utilization associated with autoso-
mal dominant polycystic kidney disease (ADPKD) was estimated across two sub-
groups; individuals with ADPKD and end-stage renal disease (ESRD) and those with 
ADPKD but without ESRD. MethOds: Study data were from a large administrative 
claims and enrollment database. Individuals 18 y/o or older, enrolled in tracked 
health plans for 12 months from April 1, 2011 through March 31, 2012, and with an 
ICD-9-CM diagnosis code for “polycystic kidney, autosomal dominant” (753.13) or 
for “polycystic kidney, unspecified type (753.12) were identified as having ADPKD, 
and linked one-to-one with individuals without ADPKD on age and gender. ESRD 
was identified by presence of ICD-9-CM code 585.6. Zero-inflated negative bino-
mial models estimated incremental hospitalizations, hospital days, outpatient 
visits, and emergency room visits for each sub-group, adjusting for age, gender, 
Charlson co-morbidity index, cardiovascular disease, diabetes and geographical 
region. Results: A total of 3,844 individuals with ADPKD who satisfied selection 
criteria were linked one-to-one with 3,844 individuals without ADPKD. Among per-
sons with ADPKD, 644 had a diagnosis of ESRD. The sample was 53% female and 
55% were between 45 to 64 years old. Incremental mean (standard error) resource 
utilization associated with ADPKD with ESRD as compared to persons without 
ADPKD was 0.35 (0.052) or 35 additional hospitalizations per 100 patients, 2.5 (0.42) 
or 250 hospital days per 100 patients, and 24.0 (1.2) or 2,400 outpatient visits per 100 
patients. Incremental mean (standard error) resource utilization associated with 
ADPKD but without ESRD as compared to persons without ADPKD was 0.065 (0.028) 
or 6.5 additional hospitalizations per 100 patients, 0.5 (0.091) or 50 hospital days per 
100 patients, and 4.4 (0.41) or 440 outpatient visits per 100 patients. cOnclusiOns: 
ADPKD was associated with incrementally greater health care resource utilization 
even before patients reached ESRD.
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Objectives: This study evaluated treatment patterns and costs among patients 
with pancreatic cancer (PC). MethOds: A retrospective study analyzed data span-
ning January 2008-June 2012 from 3 large integrated claims databases. Adult patients 
with a diagnosis of PC (ICD-9 157.xx) were included if they had a minimum eligibility 
of 12 months prior and 3 months following their first PC diagnosis and had no diag-
nosis of cancer in the pre-period. Patients were categorized as having exocrine PC 
(ICD-9 157.0-157.3; 157.8-157.9), endocrine PC (ICD-9 157.4), or metastatic-exocrine 
PC (ICD-9 157.0-157.3; 157.8-157.9, 196.xx-199.xx). Treatment patterns, health care 
resource use, and all-cause costs (2012 USD) were evaluated after cancer diagno-
sis. Results: There were 2901, 6119, and 464 patients in each of the 3 databases 
meeting all inclusion criteria, respectively. The majority of patients had exocrine PC 
(97%-98%), with 40%-76% having metastatic disease. Patients were on average 60.3-
64.5 (±11.3-14.0) years of age and 43%-52% were female. No treatment was received 
by 35%-55% of patients, 36%-55% of patients received chemotherapy ± radiation 
and/or surgery, and 9%-10% received radiation and/or surgery without chemother-
apy. Second and third-line chemotherapy was received by 17%-32% and 9%-17% 
of patients, respectively. Among those with exocrine PC, patients with metastatic 
disease experienced an average of 0.25-0.31 inpatient, 2.3-2.9 office, 3.0-4.0 other 
outpatient visits and received 4.2-5.1 prescriptions per month vs 0.09-0.11 inpatient 
visits, 1.3-1.7 office visits, 1.3-1.9 other outpatient visits and 3.2-4.1 prescriptions per 
month in those without metastatic disease. Total monthly costs averaged $9,478-
$12,042 and $1,022-$3,084 in patients with and without metastatic disease, respec-
tively. The majority of costs were attributable to medical services ($7,977-$11,212 and 
$697-$2,852, respectively), with pharmacy costs contributing to a small proportion 
of the total costs ($830-$1,501 and $232-$326, respectively). cOnclusiOns: Health 
care resource utilization and costs are highest among those with metastatic PC, 
totaling as much as $12,042 per month.
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Objectives: In 2013 a change in WHO guidelines increased the number of people 
recommended to start antiretroviral treatment (ARVs) from 16 to 28 million world-
wide; at present around 10 million are enrolled in care. Additionally the number 
of people requiring second line antiretrovirals (ARVs) is increasing. Much of this 
burden is in Sub Saharan Africa (SSA). The Infectious Diseases Institute (IDI) in 
Kampala, Uganda runs a clinic of 8000 patients; some of these have been on ARVs 
for > 10 years. The objective of this study was to analyze actual costs of different 
patient subgroups per year at IDI. MethOds: We use a fully digitalized electronic 
patient management system (ICEA), which records individual patient data includ-
ing all visit information. We linked ICEA to Navision accountancy software, in order 
to determine the actual cost of patient care from October 2012-October 2013. The 
analysis was conducted from a provider perspective. We calculated the average cost 
PHS39
dIrect medIcal coSt of comPlIcatIonS In PatIentS WItH non 
valvular atrIal fIBrIllatIon at tHe SocIal SecurIty In Peru
Sanabria C1, Cabrejos J1, Guevara C2, Olortegui A2, Garrido Lecca S3
1Universidad Nacional Mayor de San Marcos, Lima, Peru, 2Instituto Nacional Cardiovascular 
(INCOR) del Seguro Social de Salud del Perú, Lima, Peru, 3Bristol-Myers Squibb, Lima, Peru
Objectives: Estimate direct medical costs of selected acute complications in 
patients with non-valvular atrial fibrillation (NVAF) at the Social Security (EsSalud) 
in Peru. MethOds: The electronic database of EsSalud´s reference hospital: Hospital 
Nacional Guillermo Almenara Irigoyen (HNGAI) was used to identify the study popu-
lation. International Classification of Diseases (ICD) 10 codes were used to identify 
patients with NVAF and select complications of AF. Complications of interest are: 
ischemic stroke, hemorrhagic stroke, systemic embolism and myocardial infarction. 
Stroke events were classified by severity as mild, moderate, severe or fatal. All cases 
from 2011 -2012 meeting the inclusion criteria were reviewed. Patient level data from 
clinical charts was extracted to estimate resource utilization per patient per event. 
Costs were estimated using EsSalud´s 2013 tariffs manual and expressed per patient 
in 2013 USD. Results: Ischemic stroke costs were estimated at $1,259, $1,818, $ 4,910, 
and $2,829.19 for mild, moderate, severe and fatal events, respectively. Hemmorhagic 
stroke were estimated at $1,707, $2,419, $11,991 and $2,111 for mild, moderate, severe 
and fatal event, respectively. Systemic embolism and myocardial infarction were esti-
mated to cost $1,707 and $1,703 respectively. cOnclusiOns: For AF patients within 
EsSalud, hemorrhagic stroke costs are higher than those estimated for ischemic 
stroke. As expected, costs increase as the severity of the event increase. These cost 
estimates can be used as patient-level costs inputs for economic model analysis of 
AF and its complications, from the perspective of EsSalud in Peru.
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Objectives: To describe Health Care Pathway and cost evaluation of patients with 
osteoporosis. MethOds: From ARNO Observatory, an Italian population database 
which provides comprehensive data referred to patient as: drug prescription, hospi-
tal discharges, imaging, lab tests and diagnostic examination, we analyzed a cohort 
of 185.489 subjects with osteoporosis in year 2011. A group without osteoporosis, 
matched by age, gender and LHU was compared to estimate differences in health 
costs and burden of disease. Results: On a population of 5,313,167 over 40 years, 
we identified 185,489 patients treated with osteoporosis drugs (prevalence 3.5%). 
Prevalence rate is higher in female than male (6.1% vs 0.1%), modal value on 70-79 
years. The average yearly cost/patient is 2.329€ , 53% more than pair-matched group. 
This cost is due for 38.4% to drugs (31% specific drugs, 69% others), 42.8% to hos-
pitalization and 18.8% to lab tests and diagnostic examinations. Most common 
specific drugs are bisphosphonates (81%), strontium ranelatum (21%), parathy-
roid hormone (1.2%) and SERMs (0.9%). A considerable percentage (24.8%) did not 
received vitamin D supplements in association. Compared to control group, patients 
with osteoporosis received more drugs expression of higher comorbidity (corticos-
teroids +70%, nervous system drugs +42%, PPI +33%) and were more frequently 
hospitalized, beyond fractures, for arthritis (+99%, p< 0.01) and chronic bronchitis 
(+52%, p< 0.01). Less than 50% of patients controlled their serum calcium levels in 
the last three years, 32% performed a densitometry and less than a fifth a radiog-
raphy. cOnclusiOns: A big data infrastructure is a valid instrument to evaluate 
patient care pathways, monitor the good practice of treatment and estimate cost 
of illness. In a large community setting of osteoporotic patients, the lack of supple-
ment of vitamin D undermines the effectiveness of the specific pharmacological 
treatment. Despite low diagnostic approach, patients cost as much to the National 
Health System especially due to their frequent co-morbidities.
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Objectives: Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), and 
Psoriatic Arthritis (PA) are rheumatic diseases which destroy articulations and limit 
their functions. The evolution of these conditions cause important physical impair-
ment, which leads to disability, work loss, self-sufficiency, and QoL deterioration, 
among others. The objective is to estimate the economic impact of three rheumatic 
diseases: Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis 
during 2011 using registries of the main Social Security Institution in the country 
called Instituto Mexicano del Seguro Social (IMSS). MethOds: It was review all 
registries related to the indications mentioned at different settings of care: ambula-
tory visits to GP and specialist, emergency room (ER), and hospital discharge (HD) 
of IMSS from January 1st to December 31st, 2011. Based on this information it was 
calculated the cost of care using unitary cost published by the Institution according 
to the type of service and the hospital DRG implicated. Results: In 2011 the IMSS 
provided 45,528 consultations for AS, 51% were for patients between 30-49 years-old. 
28,716 (63%) were for GP; 16,257 (36%) specialist; 555 (1%) ER, and 91 HD. For JIA, there 
were 6,285 consultations; 1,766 (28%) were for GP; 4326 (69%) for specialist; 193 (3%) 
ER, and 103 HD. For PA there were 1,587 consultations; 619 (39%) for GP; 873 (55%) 
specialist; 95 (6%) ER, and 195 HD. The costs of the three diseases at IMSS during 
2011 were: AS = US $2.94 million, JIA = US $0.68 million and PA= US $0.37 million. 
The total cost of the three was US $4 millions (ER 1US= 13MXN). cOnclusiOns: 
These diseases affect quality of life and ability to work, considerably. Therefore, the 
cost of the three diseases might be underestimated due to productivity loss which 
is not included in the cost.
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hospitalized for ≥ 2 days (hospitalized patients; HPs), or using emergency room (ER) 
or observation for 1 day (emergency room patients; ERPs). Reimbursements were 
based on claims and inflated to 2010 USD; costs were derived from 2010 Premier 
data. Net reimbursement was analyzed by MS-DRG and length of stay (LOS). The 
risk of all-cause hospitalization and factors correlated with LOS were determined 
using regression modeling. Results: Across all study years, the median age was 
71 for HPs, 65 for ERPs. Median Charlson Comorbidity Index (CCI) was 4 for HPs and 
2 for ERPs. HPs had more cellulitis on the leg or surgical infection; ERPs had more 
cellulitis on the face, trunk, or arm. Median HP LOS was 4 days; 33% of patients had 
LOS > 6 days. Age, race, and history of bacterial infection were correlated with LOS. 
Median all-cause, ABSSSI-related and index event costs during the index quarter 
for patients with a principle ABSSSI diagnosis were $9,930, $6,123 and $5,604 for 
HPs and $1,127, $108 and $100 for ERPs respectively. cOnclusiOns: HPs were older 
and sicker than ERPs, with more cellulitis on the leg and post-operative infections. 
Further research and analysis may help determine whether treating some hospital-
ized patients with less comorbidity in the ambulatory setting might result in lower 
costs per patient after controlling for these factors.
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Objectives: The aims of this study were to determine the clinical consequences 
and non-pharmacological costs of the usage of oral anticoagulation (OAC) therapy 
for the treatment of atrial fibrillation (AF) at EsSalud in Peru. MethOds: A markov 
model was adapted to evaluate the clinical and economic impact of OAC on a cohort 
of 1,000 patients among the AF vitamin K antagonists (VKA) suitable population 
at EsSalud in Peru. Comparators for the analysis are: apixaban 5mg BID, warfarin 
5mg and aspirin 150mg. A lifetime horizon and EsSalud´s perspective were used. 
A discount rate of 3.5% was applied to both costs and outcomes. Efficacy data was 
taken from the clinical trials for apixaban, ARISTOTLE and AVERROES, which directly 
compared apixaban with warfarin and apixaban with aspirin, respectively. Resource 
utilization for each event was collected from a clinical chart review at a specialized 
care center of EsSalud. All costs were taken from EsSalud´s 2013 tarrifs and are 
expressed in 2013 US dollars. Results were validated by an expert panel of clinicians 
from EsSalud. Results: The number of events associated with each anticoagu-
lant therapy (apixaban, warfarin and aspirin respectively) were: stroke (ischemic 
and hemorrhagic) and systemic embolism 309, 352, 352, major bleedings 116, 149, 
102; and event related deaths 401, 447, 445, respectively. Apixaban was associated 
with a reduction of the non-pharmacological costs when compared with warfarin 
and aspirin in the range of $245 – $1,282. cOnclusiOns: Over a lifetime horizon 
apixaban demonstrates a reduction in the number of AF complication events and 
reduction in non-pharmacological costs at EsSalud.
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Objectives: To asses the costs and financial consequences of epidemiological 
changes for chronic diseases (HYPERTENSION AND DIABETES) in a middle-income 
country. MethOds: An evaluative approach based on a longitudinal design was 
used. Direct costs were determined for the functions of production, standards of 
quality and the estimation of inputs costs. Indirect costs were determined by using a 
human capital model for Latin America which uses indicators of premature mortal-
ity and disability (temporary or permanent). Probabilistic models were developed 
to estimate epidemiological changes during 2010-2012 by using the Box-Jenkins 
technique. Finally, the economic burden was obtained for disease by applying an 
econometric adjustment factor. Results: Taking hypertension results, compar-
ing the economic impact in 2010 versus 2012 (p< 0.05), there is a 24% increase in 
financial requirements. The total amount for hypertension in 2011 (US dollars) was 
$ 5733,350,291. It include $ 2718,280,941 in direct costs and $ 3015,069,350. Costs for 
hypertension are permanently increasing in regards to economic burden, showing 
an increase of 33%. This average has differences for insured and uninsured popula-
tions. cOnclusiOns: Health care systems and society in middle income countries 
will face important challenges on health financing, universal effective coverage and 
financial protection for the uninsured, if the risk factors and the health care model 
remain as currently are. The major economic impact of chronic diseases will be in 
users out of pocket expenditures because of indirect costs. We suggest an important 
reorganization of the planning process, the health care model and the allocation of 
resources mechanisms, in order to strengthen health care and access to hospital 
and outpatient services for patients suffering a chronic disease.
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Objectives: Visual loss is significantly associated with increased risk of mortality 
and decreased quality of life. In Prince Edward Island (PEI), Canada, eye examination 
and cost of eyeglasses are not covered by provincial health insurance. This study 
aimed to assess the cost-effectiveness of insured eye examination compared to non-
insured eye examination for PEI residents. MethOds: A cost-effectiveness analysis 
was conducted from a perspective of Canada’s health care system. A target popula-
tion was a PEI resident aged 42 years or older. Risk of vision loss and utility data were 
of care for different categories of patients including cost of health care provider time 
per visit, lab tests, ARV drugs and non ARV drugs. Results: The cost of treatment 
for an HIV positive patient with a CD4 count > 350 cells/ uL who has not started 
ART was $51/year. The cost of treating a patient on first line therapy in the first 
year of ART was $218, and thereafter $284/yr. The cost of a patient on second line 
ART was $1393/year. The cost of treatment of pregnant and patients co-infected 
with M. tuberculosis was $229/year and $413/year respectively. The costs are driven 
predominantly by ARV costs. cOnclusiOns: This analysis shows the actual costs 
of HIV care at a larger urban HIV clinic in SSA. The increasing number of patients on 
second line ARVs is likely to dramatically increase the financial burden on health 
services in SSA in the future.
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Objectives: Approaches for predicting cost accumulation for heterogeneous 
samples are limited. We employ the Grouping Algorithm for Cancer Cost Data 
(GACCD) to investigate cost accumulation over time and identify ‘high cost’ 
patients. MethOds: Two-fold cross validation was used to evaluate survival and 
cost accumulation using linked prostate cancer (PCa) registry and Medicare claims 
data from 1999-2009. Patients were grouped according to a refined similarity metric 
using five patient characteristics (cancer stage, age, Charlson Comorbidity Index 
(CCI), performance proxy indicator, race). Cost accumulation was evaluated in the 
test dataset for the GACCD groups identified in the training data. Curves using the 
test data plotted inverse probability weighted cumulative average total monthly 
costs (CATMC) for the post-diagnosis period and the proportion of people who were 
deemed to be ‘high cost’. Results: Application of the inclusion criteria resulted in 
110,824 patients. Median (mean) follow up was 48 (51) months and the mortality rate 
was 27.3%. The five GACCD groups had distinguishing characteristics e.g., group2 
patients were typically older, with CCI above 2 and/or diagnosed with either later 
stage or unstaged PCa; group3 patients were typically younger, with CCI= 0 and diag-
nosed with early stage PCa. Cost accumulation within the first three years varied 
across the groups, with the lowest (highest) rate in group3 (group2) in the training 
dataset. Using the test data: at a threshold of $10,000 in CATMC, the proportion of 
patients that was high cost within three years following diagnosis ranged from 
82% in group3 to 90% in group2; proportions ranged from 45% in group3 to over 
60% in group2 at a threshold of $25,000; proportions ranged from 15% in group3 to 
over 30% in group2 at a threshold of $50,000. cOnclusiOns: A grouping algorithm 
with a refined similarity metric can identify patient subgroups that will accumulate 
higher costs over time.
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Objectives: (1)Survey to estimate the monthly expenditure of a Type II Diabetes 
patient in Mumbai . (2)To project the fact that even in absence of health insurance 
policies by government for its citizens, patients receive free or cost subsidized treat-
ment in the government hospitals. (3)Explore government initiatives in regulating 
the price of the Diabetes II drugs. MethOds: Three sets of structured question-
naires were designed which captured the patient demographics,prescription trends 
of type II Diabetes patients in Mumbai,India.The survey through questionnaires tar-
geted three government secondary hospitals,two government tertiary hospitals,35 
General Practioners,50 Drug stores. Results: (1) 46%of the patients detected with 
type II Diabetes lie in the age group of 50-60 years. (2)Amongst them the population 
of males affected is little more than females ie.51% males vs 46% females. (3)The 
trend of drugs as prescribed by the General Practioners is same as that of drug pre-
scriptions received by drug stores.The Metformin containing generic brands which 
fall under The Drug Price Control Order(DPCO) 2013 (cap price removed)is majorly 
prescribed followed by glypizides , acarbose and pioglitazone containing generic 
brands. cOnclusiOns: : (1)The monthly expenditure of a Type II Diabetes patient in 
Mumbai is Rs.300 (USD 4.8)when the patient is treated by GP and purchases the drug 
from the drug stores. (2)The patients are either treated free or in subsidized rates 
in government hospitals.ie.in 2.4USD per month. (3)The metformin category drugs 
coming under DPCO 2013 are the majorly prescribed drugs. Thus it is very easy and 
convenient for type II Diabetes patients in Mumbai to suffice their medical needs in 
the most reasonable and affordable price and also get free treatment from tertiary 
government hospitals.Although a federal/government health insurance policy does 
not exist in India the government through its subsidies or free treatments rightly 
makes this therapy accessible to the common man of the city.
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Objectives: Recent clinical trials of antibiotics targeted to ABSSSI have included 
large proportions of patients treated in the ambulatory setting. An objective of 
this study of real-world patient transaction data was to analyze differences 
between Medicare patients treated in the inpatient versus the ambulatory set-
ting. MethOds: Analysis used Medicare 5% Limited Data Set (LDS) files contain-
ing claims for 27,607 patients age ≥ 18 with a principal diagnosis of ABSSSI between 
Q4, 2007 – Q3, 2010 from a 5% sample of Medicare beneficiaries, including patients 
